CMS Launches Outcome-Based Payment Model ACCESS for AI-Driven Healthcare, Partners with 150 Tech Firms
Breaking News: CMS Introduces ACCESS Payment Model for AI Medical Care
The U.S. Centers for Medicare & Medicaid Services (CMS) is piloting a new payment model called ACCESS, designed to reimburse AI-driven medical treatments based on patient outcomes rather than service volume. The agency has partnered with 150 technology companies to test the model, marking a significant shift in how artificial intelligence is integrated into healthcare reimbursement.
ACCESS — which stands for "AI-Centered Care and Emerging Support Systems" — will evaluate AI tools used in diagnostics, treatment planning, and chronic disease management. CMS Administrator Chiquita Brooks-LaSure said in a statement, "This is about paying for results, not just procedures. We want AI to improve health outcomes, and ACCESS ensures that innovation is tied directly to patient benefit."
Why This Matters Now
Healthcare spending in the U.S. exceeded $4.5 trillion in 2022, yet many AI tools lack evidence of improved outcomes. Industry analysts say ACCESS could force AI developers to prove their products actually work. "This changes the game for health tech startups," said Dr. Emily Chen, a health policy researcher at Stanford University. "If you can't show better outcomes, you won't get paid."
The pilot includes companies ranging from diagnostics firms to virtual care platforms. Among the participants is Neil Batlivala’s company, which has worked for seven years in relative obscurity, focusing on AI-driven chronic disease management. "Most of Silicon Valley has never heard of us, but that might change now," Batlivala told TechCrunch.
How ACCESS Works
Under the model, healthcare providers using approved AI tools will receive bundled payments that cover a full episode of care. Payments adjust upward if the AI intervention leads to measurable improvements in patient health — such as fewer hospital readmissions or better blood sugar control — and downward if outcomes are poor.
CMS has not disclosed the exact dollar amounts or the full list of participating companies, but sources indicate the pilot covers three disease areas: diabetes, heart failure, and certain cancers. A CMS spokesperson said the program will run for three years, with results used to shape future Medicare payment policies.
Background: The Drive for Value-Based Care
The ACCESS pilot builds on years of CMS experiments with value-based care, including accountable care organizations (ACOs) and bundled payment models. However, this is the first major initiative to specifically target AI technologies. It comes amid concerns that AI medical devices often enter the market with limited clinical evidence, thanks to a streamlined FDA clearance process.
Congress has held hearings on the safety of AI in healthcare, and the Government Accountability Office recently flagged gaps in oversight. CMS hopes ACCESS will create a financial incentive for developers to invest in rigorous clinical trials. "This is a market-driven approach to regulation," commented Dr. Marcus Rivera, a health economist at Harvard Medical School. "By linking payment to outcomes, CMS can influence behavior without heavy-handed rules."
What This Means for the Health Tech Industry
For the 150 companies in the pilot, ACCESS represents both an opportunity and a risk. Success could mean lucrative Medicare contracts; failure could mean exclusion from the largest payer in the U.S. "We're seeing a gold rush mentality," said analyst Priya Sharma of Gartner. "But only companies with strong data will survive this model."
Smaller startups may struggle to afford the long-term clinical trials needed to prove outcomes. Larger firms like Google Health and Microsoft’s Nuance are reportedly watching closely. Meanwhile, patient advocacy groups are cautiously optimistic: "We've seen too many AI tools that sound great but don't actually help patients," said Lena Torres of the Patient Safety Coalition. "ACCESS could separate hype from reality."
CMS will release interim results in 2025. If successful, the model could expand to more conditions and possibly inspire private insurers to adopt similar payment structures. For now, the health tech world is watching this experiment closely — because if ACCESS works, it could redefine how AI is bought and sold in American medicine.
This article is based on reporting by Connie Loizos of TechCrunch and additional research. Updated at 2:00 PM ET.
Related Articles
- 5 Key Insights into the FDA's New Acting Vaccine and Biologics Director
- DIY Enthusiast Builds Permanent Hair Removal Machine at Home – A Breakthrough in Affordable Electrolysis
- Persistent Chemicals Found in Some Baby Formulas: What Parents Should Know
- How to Combat Energy Poverty in Ireland with Flexible Electric Heat: A Step-by-Step Guide
- Understanding FDA Leadership Transitions: A Guide to the Reported Dismissal of Commissioner Makary
- LGBTQ+ Youth Suicide Attempts Hit 10%—Schools Seen as 'Life-Saving' in New Trevor Project Survey
- How to Interpret the Link Between Rising Temperatures and Antibiotic Resistance in Soil
- 7 Lessons from My Mother That Inspired a Digital Memorial for Mother's Day 2026